Advertisement

Sensitivity of Therapeutic Trials: Sequential Analysis: Peeking at Interim Results: Is it Scientific? Is it Ethical?

  • D. R. Laurence
Part of the NATO Advanced Study Institutes Series book series (NSSA, volume 39)

Abstract

Therapeutic trials are always expensive in terms of time of highly trained medical/scientific personnel and often in terms of money for extra staff and supporting service. They are also tedious to perform even where positive results may be expected. Therefore, it is important that they should be neither larger nor more prolonged than is necessary to obtain a definite result. This is easy to say but hard to do.

Keywords

Therapeutic Trial Sequential Plan Random Pairing Repeat Examination Tetanus Antitoxin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    J.W. Tukey, Some thoughts on clinical trials, especially problems of multiplicity, Science, 198: 679 (1977)PubMedCrossRefGoogle Scholar
  2. 2.
    R. Peto, M.C. Pike, P. Armitage, N.E. Breslow, D.R. Cox, S.V. Howard, N. Mantel, K. McPherson, J. Peto and P.G. Smith, Design and analysis of randomized clinical trials requiring prolonged observation of each patient, Br.J.Cancer, 34: 585 (1976). 35: 1 (1977)PubMedCrossRefGoogle Scholar
  3. 3.
    P. Armitage, Sequential Medical Trials, Blackwell, Oxford (1975)Google Scholar
  4. 4.
    A. Brown, S.D. Mohamed, R.D. Montgomery, P. Armitage and D.R. Laurence, Value of a large dose of antitoxin in clinical tetanus, Lancet, 1: 227 (1960)CrossRefGoogle Scholar
  5. 5.
    A.O. Lucas, A.J. Willis, S.D. Mohamed, R.D. Montgomery, H. Steiner, P. Armitage and D.R. Laurence, A comparison of the value of 500,000 IU tetanus antitoxin (horse) with 200,000 IU in the treatment of tetanus, Clin.Pharmacol. Therap. 6: 592 (1965)Google Scholar
  6. 6.
    B.J. Vakil, T.H. Tulpule, P. Armitage and D.R. Laurence, A comparison of the value of 200,000 IU tetanus antitoxin with 50,000 IU in the treatment of tetanus, Clin.Pharmacol. Therap., 4: 182 (1963)Google Scholar
  7. 7.
    B.J. Vakil, T.H. Tulpule, P. Armitage and D.R. Laurence, A comparison of the value of 200,000 IU tetanus antitoxin (horse) with 20,000 IU in the treatment of tetanus, Clin. Pharmacol.Therap., 5: 695 (1964)Google Scholar
  8. 8.
    B.J. Vakil, T.H. Tulpule, P. Armitage and D.R. Laurence, A comparison of the value of 200,000 IU tetanus antitoxin (horse) with 10,000 IU in the treatment of tetanus, Clin. Pharmacol.Therap. 9: 465 (1968)Google Scholar
  9. 9.
    B.J. Vakil, P. Armitage, R.E. Clifford and D.R. Laurence, Therapeutic trial of intracisternal human tetanus immunoglobulin in clinical tetanus, Trans.Roy.Soc.Trop.Med.Hyg., 73: 579 (1979)PubMedCrossRefGoogle Scholar
  10. 10.
    Ditchley Report, The scientific and ethical basis of the clinical evaluation of medicines, Eur. J. Clin. Pharmacol. 18: 129 (1980)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1981

Authors and Affiliations

  • D. R. Laurence
    • 1
  1. 1.Department of Clinical PharmacologySchool of Medicine, University College LondonLondonUK

Personalised recommendations